Search

Displaying results 1131 - 1140 of 7604 in total
  1. Drug

    Cabazitaxel

    go.drugbank.com/drugs/DB06772
    ApprovedInvestigational

    [A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376] … [A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010.

  2. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age … Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone

  3. Drug

    Etoricoxib

    go.drugbank.com/drugs/DB01628
    ApprovedInvestigationalWithdrawn

    It is approved in more than 60 countries worldwide but not in the US. … Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid.

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal
  4. Drug

    Azacitidine

    go.drugbank.com/drugs/DB00928
    ApprovedInvestigational

    myeloid leukemia (AML), two types of cancer characterized by the presence of aberrant DNA methylation. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]

  5. Drug

    Pectin

    go.drugbank.com/drugs/DB11158
    ApprovedInvestigationalVet approved

    This status allows pectin to be used with no limitations.[L1960]

    Mixtures: NEO ASTA, NEO DIAFORM
  6. Drug

    Nelarabine

    go.drugbank.com/drugs/DB01280
    ApprovedInvestigational

    [A258719] Nelarabine was first granted accelerated approval by the FDA on October 28, 2005, and was manufactured under the trademark name ARRANON by GlaxoSmithKline. … [A2332] Due to the rarity of these T-cell malignancies, nelarabine was first granted orphan drug status and a fast-track designation by the FDA to address the unmet therapeutic needs of these cancers.

  7. Drug

    Palonosetron

    go.drugbank.com/drugs/DB00377
    ApprovedInvestigational

    HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by … As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Neostigmine

    go.drugbank.com/drugs/DB01400
    ApprovedInvestigationalVet approved

    Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. … A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine.

    Synonyms: 3-Trimethylammoniumphenyl N,N-dimethylcarbamate
  9. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.

    Categories: Analgesics, Non-Narcotic
  10. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). … APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot

    Mixtures: Beriplex P/n 500, Beriplex P/n 1000